GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Evofem Biosciences EVFM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.01

+2.38%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Evofem Biosciences — daily EVFM Delayed
Market value
$485,012
Last close × shares
Volume
80.7k
Shares, 9 Nov 2026
Price to earnings
1.1

About Evofem Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Evofem Biosciences is based in San Diego, California and is incorporated in Delaware. Its shares trade on OTC under the ticker EVFM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $20.2m and net income of $391,000. At that date it held total assets of $20.3m and shareholders' equity of −$74.3m.

In its own words

No. 539. August 2025. Data table for Figure 1, sourced from National Survey of Family Growth (NSFG) 2022–2023.

U.S. is the largest commercial market worldwide and presents the greatest opportunity for PHEXX and other women’s health products.

J. Current Contraceptive Status Among Females Ages 15–49: United States, 2022–2023. NCHS Data Brief Number 539. August 2025.

539. August 2025. Accessed Jan. 9, 2026, via https://www.cdc.gov/nchs/data/databriefs/db539.pdf.

We believe PHEXX can be prescribed to help prevent unintended pregnancy in these patients.

The quick and easy pre-sex application is designed with spontaneity and convenience in mind.

Health Survey. Nov 22, 2024. Accessed Jan 7, 2026, via https://www.kff.org/womens-health-policy/contraceptive-experiences-coverage-and-preferencesfindings-from-the-2024-kff-womens-health-survey/#:~:text=Eight%20in%20ten%20(82%25)%20women,Almost%20half%20(48%25)%20of%20contraceptive.

E, et al. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception.

3,000 HCPs within the OB/GYN space, with a particular focus on current SOLOSEC prescribers and established relationships of our experienced sales team.

Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗

More about Evofem Biosciences →

How it makes its money

Revenue, year to 31 Dec 2023

  • Phexxi [Member] $18.2m · 99.9%

Latest on Evofem Biosciences

Our reporting

We have not reported on Evofem Biosciences yet.

Next results

12 Nov 2026

Due on 12 Nov 2026. Analysts expect earnings of -914.06 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Evofem Biosciences's ticker?

Evofem Biosciences trades as EVFM on its US listing, under ISIN US30048L3024.

What was Evofem Biosciences's last closing price?

0.01 on 9 Nov 2026. The figure is in USD and is never converted.

When does Evofem Biosciences next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.